{"entity":{"id":"nct05498428","kind":"trial","name":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of Amivantamab, Lazertinib, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Janssen Research & Development, LLC, now recruiting.","summary":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05498428 by Janssen Research & Development, LLC, with 520 participants planned, started 2022-11-11 and due to reach its primary completion in 2027-08-17. Interventions recorded: Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC) and Low Molecular Weight Heparin (LMWH).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05498428","url":"https://clinicaltrials.gov/study/NCT05498428"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","egfr-mutant-nsclc"],"sections":[],"technologies":["bispecific-antibody"],"targets":[],"drugs":["amivantamab","lazertinib","carboplatin","pemetrexed"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05498428","phase":"2","setting":"A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer","sponsor":"Janssen Research & Development, LLC","participation":[{"nct":"NCT05498428","source":"https://clinicaltrials.gov/study/NCT05498428","fetchedAt":"2026-10-07T16:53:44.279Z","studySha256":"f75d92980a9be7902584b6a60fe281123c5bc628a6c2a4fe3f6224139fe0d54e","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-28","leadSponsor":"Janssen Research & Development, LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":520,"enrolmentType":"ESTIMATED","siteCount":110,"recruitingSiteCount":82,"countries":["Brazil","China","France","Germany","Israel","Italy","Japan","Malaysia","South Korea","Spain","United Kingdom","United States"]}],"started":"2022-11-11","startedType":"actual","enrolled":520,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05498428/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"}],"drug":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"lazertinib","kind":"drug","name":"Lazertinib","route":"/drugs/lazertinib/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}